Avitide Overview

  • Founded
  • 2012

Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 34

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $275M

Avitide General Information

Description

Developer a molecule-specific affinity purification technology designed to improve drug safety and establish bio similarity. The company's technology focuses on purifying therapeutic proteins, and uses rapid development of chromatography resins via chemical synthesis, enabling partners to achieve speeded bioprocess development timelines, reduced program risk, predictable commercial scalability, and lower cost of manufacturing for batch and continuous operations.

Contact Information

Website
www.avitide.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Parent Company
Repligen
Primary Office
  • 16 Cavendish Court
  • Lebanon, NH 03766
  • United States
+1 (603) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Avitide Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 30-Sep-2021 $275M 000.00 00000 Completed Generating Revenue
8. Later Stage VC (Series H) 23-Oct-2019 0000 000.00 00000 Completed Generating Revenue
7. Later Stage VC (Series G) 23-Aug-2018 00.000 000.00 00000 Completed Generating Revenue
6. Later Stage VC (Series F) 02-Jan-2018 000 000.00 00000 Completed Generating Revenue
5. Later Stage VC (Series E) 26-Jun-2017 0000 000.00 0000 Completed Generating Revenue
4. Later Stage VC (Series D) 12-Sep-2016 000 000.00 000.00 Completed Generating Revenue
3. Later Stage VC (Series C) 06-Aug-2015 00.00 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 09-Jun-2014 $3.44M $4.89M 000.00 Completed Startup
1. Early Stage VC (Series A) 04-Mar-2013 $1.45M $1.45M 00.000 Completed Startup
To view Avitide’s complete valuation and funding history, request access »

Avitide Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series H 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series G 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series F 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series E 000,000 00.000000 000.00 000.00 00 000.00 00.000
Series D 000,000 00.000000 00.00 00.00 00 00.00 0.000
Series C 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 918,450 $0.000100 $3.74 $3.74 1x $3.74 10.92%
Series A 783,422 $0.000100 $1.87 $1.87 1x $1.87 9.32%
To view Avitide’s complete cap table history, request access »

Avitide Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer a molecule-specific affinity purification technology designed to improve drug safety and establish bio similar
Biotechnology
Lebanon, NH
34 As of 2021
000.00
0000 0000-00-00
000000&0 000.00

000000

re eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sun
0000000000000
Seoul, South Korea
00 As of 0000
0000
0000000000 0 0000

000000

o eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim v
0000000000000
Fremont, CA
000 As of 0000
000.00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Avitide Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ToolGen Corporation Seoul, South Korea 00 0000 0000000000 0 0000
00000000 000000000 Formerly VC-backed Fremont, CA 000 000.00 000000&0 000.00
000000 00000000000 Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
000000 00000000 Venture Capital-Backed Cambridge, United Kingdom 00 000.00 0000000000 0 000.00
0000000000 Venture Capital-Backed South San Francisco, CA 00 000.00 0000000000 0 000.00
You’re viewing 5 of 28 competitors. Get the full list »

Avitide Executive Team (8)

Name Title Board Seat Contact Info
Kevin Isett Ph.D Co-Founder & Chief Executive Officer
Scott Kennedy Vice President & Chief Financial Officer
Warren Kett Ph.D Co-Founder & Chief Scientific Officer
Errik Anderson Co-Founder
Tillman Gerngross Ph.D Co-Founder
You’re viewing 5 of 8 executive team members. Get the full list »

Avitide Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Avitide Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Angeli Parvi Angel Group Minority 000 0000 000000 0
Borealis Ventures Venture Capital Minority 000 0000 000000 0
Hoyoung Huh Angel (individual) Minority 000 0000 000000 0
John Ballard Angel (individual) Minority 000 0000 000000 0
Mithril Capital Management Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial